N/A
Completed N=96
Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes
Source: ClinicalTrials.gov NCT02488785 ↗Enrolled (actual)
96
Serious AEs
—
Results posted
Sep 2022
Primary outcomePrimary: Hemoglobin A1c — 8.41; 8.18 percentage of A1C
Summary
The goal of this study is to evaluate the impact of a comprehensive diabetes education and management program based on frequent communication with patients using teleconsultation, text messaging, and phone calls on diabetes related outcomes in Latino patients with type 2 diabetes. The investigators hypothesize that the decline in hemoglobin A1c value between the baseline and the six-month visit will be at least 0.5 percent greater in the intervention group than in the control group.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hemoglobin A1c |
8.41; 8.18 | — |
Eligibility Criteria
Inclusion Criteria
- Have physician-diagnosed type 2 diabetes
- Be self-identified as Hispanic or Latino
- An A1c value between 8-14% within the last three months.
- Demonstrate the ability, either alone or with the help of a family member that will be with the patient at least once a week, to use the technology that will be used during the teleconsultations
Exclusion Criteria
- Severe diabetes related chronic complications such as chronic renal failure, blindness, amputations, stroke, etc.
- Concomitant chronic illnesses that would affect their participation in the program, i.e. cancer, debilitating diseases, etc.
- Any other condition that would affect participant's basic mental health skills
- Type 1 diabetes or gestational diabetes
- Patients with abnormal hemoglobin, anemia or any condition that may affect red blood cell turnover. Any of these conditions may be detected through participants' history or through the laboratory report at study screening
- Signs or symptoms of metabolic decompensation (polyuria, polydypsia, polyphagia, unexplained weight loss, blurry vision, lethargy, etc.)
Data sourced from ClinicalTrials.gov (NCT02488785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.